<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389946</url>
  </required_header>
  <id_info>
    <org_study_id>BIOFLOW-V</org_study_id>
    <nct_id>NCT02389946</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions</brief_title>
  <acronym>BIOFLOW-V</acronym>
  <official_title>BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus
      Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or
      restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent
      system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIOTRONIK BIOFLOW-V clinical trial is a prospective, multicenter, randomized, controlled
      trial combining data on the randomized subjects with data from two historical studies by
      employing a Bayesian approach.

      Subjects with CAD that qualify for PCI with stenting will be screened per the protocol
      inclusion and exclusion criteria to achieve a total of up to 1,400 randomized subjects.
      Eligible subjects will be randomized in a 2:1 ratio, stratified by study center, to undergo
      percutaneous coronary revascularization with either the Orsiro Sirolimus Eluting Stent System
      (treatment group) or the Xience Everolimus Eluting Stent System (control group).

      Subjects may receive treatment of up to three target lesions, one or two target lesions per
      target vessel, for a maximum of two target vessels. The target lesion(s) must be de novo or
      restenotic lesion(s) of ≤ 36 mm in length in native coronary artery(ies), with a reference
      vessel diameter of 2.25-4.0 mm. Treatment of restenotic lesions is allowed provided that the
      target lesion was previously treated with PTCA only. All treatment with study stents is to be
      performed during a single index procedure. Note: Concurrent treatment of non-target lesions
      during the index procedure is not allowed.

      Randomized subjects will have clinical follow-up at 1 month, 6 months, 12 months and at 2, 3,
      4 and 5 years following the index procedure.

      To assess the non-inferiority of the Orsiro stent compared to the Xience stent, BIOFLOW-V
      randomized subjects will be combined with historical subjects from the BIOFLOW-II and
      BIOFLOW-IV randomized trials employing a Bayesian approach. Only subjects who meet all
      clinical and angiographic eligibility criteria of the BIOFLOW-V trial will be included in the
      analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target lesion failure (TLF) rate at 12 months post-index procedure.</measure>
    <time_frame>12-Months</time_frame>
    <description>TLF is defined as all cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (MI), or clinically driven target lesion revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success &lt; 30% residual stenosis</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using any percutaneous method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure)</time_frame>
    <description>Defined as attainment of &lt; 30% residual stenosis of the target lesion using the assigned study stent only without occurrence of in-hospital major adverse cardiac events (MACE; composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction or Cardiac Death</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE and individual MACE components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>MACE: composite of all-cause death, Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLF and individual TLF components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>TLF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) and individual TVF components</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure), 1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
    <description>TVF: composite of cardiac death, target vessel Q-wave or non-Q-wave MI, and any clinically-driven TVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>Hospital Discharge (6-24 hours post-index procedure),1, 6, 12 months, 2, 3, 4 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1334</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis, Coronary</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>Orsiro sirolimus coronary stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with a Orsiro DES.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xience everolimus coronary stent system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with a Xience DES.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro DES</intervention_name>
    <description>Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.</description>
    <arm_group_label>Orsiro sirolimus coronary stent system</arm_group_label>
    <other_name>Orsiro sirolimus coronary stent system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience DES</intervention_name>
    <arm_group_label>Xience everolimus coronary stent system</arm_group_label>
    <other_name>Xience everolimus coronary stent system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥18 years or the minimum age required for legal adult consent in the
             country of enrollment.

          2. Subject is an acceptable candidate for PCI.

          3. Subject is an acceptable candidate for CABG.

          4. Subject has clinical evidence of ischemic heart disease, stable or unstable angina
             pectoris or documented silent ischemia.

          5. Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either,
             clopidogrel, prasugrel, ticagrelor or ticlopidine.

          6. Subject has provided written informed consent.

          7. Subject is willing to comply with study follow-up requirements.

        Each target lesion/vessel must meet all of the following angiographic criteria for the
        subject to be eligible for the trial:

          1. Subject has up to three target lesions in up to two separate target vessels (two
             target lesions in one vessel and one target lesion in a separate vessel).

          2. Target lesion must be de novo or restenotic lesion in native coronary artery;
             restenotic lesion must have been treated with a standard PTCA only.

          3. Target lesion must be in major coronary artery or branch (target vessel).

          4. Target lesion must have angiographic evidence of ≥ 50% and &lt; 100% stenosis (by
             operator visual estimate). If the target lesion is &lt; 70% stenosed, clinical evidence
             of ischemia by positive functional study, CT, electrocardiography, FFR, or post
             infarct angina.

          5. TIMI flow &gt; 1.

          6. Target lesion must be ≤ 36 mm in length by operator visual estimate.

          7. Target vessel RVD of 2.25-4.0 mm by operator visual estimate.

          8. Target lesion must be treatable with a maximum of two overlapping stents.

        Exclusion Criteria:

          1. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index
             procedure. Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study
             enrollment.

          2. Subject is hemodynamically unstable.

          3. Subject is pregnant and/or breastfeeding or intends to become pregnant during the
             duration of the study.

          4. Subject has a known allergy to contrast medium that cannot be adequately
             pre-medicated, or any known allergy to thienopyridine, aspirin, both heparin and
             bivalirudin, L-605 cobalt-chromium (Co-Cr) alloy or one of its major elements (cobalt,
             chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbide, PLLA,
             sirolimus or everolimus.

          5. Revascularization of any target vessel within 9 months prior to the index procedure or
             previous PCI of any non-target vessel within 30 days prior to the index procedure.

          6. Planned treatment of a lesion not meeting angiographic inclusion and exclusion
             criteria during the index procedure or after the index procedure.

          7. Planned surgery within 6 months of index procedure unless dual antiplatelet therapy
             can be maintained throughout the peri-surgical period.

          8. History of a stroke or transient ischemic attack (TIA) within 6 months prior to the
             index procedure.

          9. Subjects with active bleeding disorders, active coagulopathy, or any other reason, who
             are ineligible for DAPT.

         10. Subject will refuse blood transfusions.

         11. Subject has documented left ventricular ejection fraction (LVEF) &lt; 30% within 90 days
             prior to the index procedure.

         12. Subject is dialysis-dependent.

         13. Subject has impaired renal function (i.e., blood creatinine &gt; 2.5 mg/dL or 221 μmol/L
             determined within 7 days prior to the index procedure).

         14. Subject has leukopenia (i.e. &lt; 3,000 white blood cells/mm3), thrombocytopenia (i.e. &lt;
             100,000 platelets/mm3) or thrombocytosis (i.e. &gt; 700,000 platelet/mm3).

         15. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids
             are permitted), or has known life-limiting immunosuppressive or autoimmune disease
             (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus
             is permitted).

         16. Subject is receiving chronic anticoagulation (e.g. coumadin, dabigatran, apixaban,
             rivaroxaban or any other agent).

         17. Subject has life expectancy of &lt; 1 year.

         18. Subject is participating in another investigational (medical device or drug) clinical
             study. Subjects may be concurrently enrolled in a post-market study, as long as the
             post-market study device, drug or protocol does not interfere with the investigational
             treatment or protocol of this study.

         19. In the investigator's opinion, subject will not be able to comply with the follow-up
             requirements.

        Subjects will be excluded from the trial if any of the target lesions/vessels meets any of
        the following angiographic criteria:

          1. Target lesion is located within a saphenous vein graft or arterial graft.

          2. Target lesion is a restenotic lesion that was previously treated with a bare metal or
             drug eluting stent (in-stent restenosis).

          3. Target lesion has any of the following characteristics:

               1. Lesion location is within the left main coronary artery, or within 3 mm of the
                  origin of the left anterior descending (LAD) or left circumflex (LCX).

               2. Involves a side branch of &gt; 2.0 mm in diameter. Note: Lesions within 3 mm of the
                  origin of the right coronary artery may be treated.

          4. Target vessel/lesion is excessively tortuous/angulated or is severely calcified, that
             would prevent complete inflation of an angioplasty balloon. This assessment should be
             based on visual estimation.

          5. Target vessel has angiographic evidence of thrombus.

          6. Target lesion is totally occluded (100% stenosis).

          7. Target vessel was treated with brachytherapy any time prior to the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Waksman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Koolen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neptune City</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butler</city>
        <state>Pennsylvania</state>
        <zip>16001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <zip>SA 5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. Am Heart J. 2017 Nov;193:35-45. doi: 10.1016/j.ahj.2017.08.001. Epub 2017 Aug 5.</citation>
    <PMID>29129253</PMID>
  </reference>
  <results_reference>
    <citation>Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R; BIOFLOW V Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21;390(10105):1843-1852. doi: 10.1016/S0140-6736(17)32249-3. Epub 2017 Aug 26.</citation>
    <PMID>28851504</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting coronary stents</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Bioabsorbable polymer</keyword>
  <keyword>DES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

